AtriCure (ATRC) Q1 2023: Open Ablation Sales Surge 32%, Expanding U.S. Cardiac Penetration

May 2, 2023 | By EarningsIQ Research

AtriCure’s Q1 2023 marked a decisive acceleration in open ablation adoption, with the Encompass Clamp fueling 32% U.S. segment growth and driving robust margin leverage. Management’s conservative guidance raise and clinical trial acceleration signal a multi-year expansion thesis, but spending discipline and execution on new product launches will determine the durability of these gains.

Summary

• Open Ablation Penetration Accelerates: Encompass Clamp adoption hit one-third of U.S. accounts, supporting strong volume and pricing gains.
• Clinical Investment Deepens: LEAPS trial enrollment outpaced expectations, positioning AtriCure for a larger addressable market in stroke prevention.
• Profitability Inflection in Sight: Margin discipline and diversified growth drivers set up for sustained EBITDA leverage, but spending will rise as R&D ramps.

Business Overview

AtriCure develops, manufactures, and sells medical devices for the treatment of atrial fibrillation (AFib) and related conditions, targeting cardiac surgeons, electrophysiologists, and hospitals. Its core franchises include open ablation (devices for surgical ablation of cardiac tissue), appendage management (AtriClip devices for left atrial appendage exclusion to reduce stroke risk), minimally invasive ablation, and pain management (CryoSphere probe for post-surgical pain). Revenue is generated through device sales in the U.S. and international markets, with open ablation and appendage management as the largest segments.

Performance Analysis

AtriCure delivered broad-based, double-digit growth across all segments, with total revenue up 25% year-over-year and 6% sequentially. Open ablation led the charge, surging 32% in the U.S., as the Encompass Clamp continued rapid adoption and favorable pricing. Appendage management and pain management posted 21% and 38% U.S. growth, respectively, reflecting expanding physician demand and new account penetration. International revenue also grew 24%, with European sales up nearly 30% on strong volume in all key product lines.

Gross margin held steady at 74.5%, balancing production efficiencies against modest supply chain cost inflation and product mix pressure. Operating expenses rose 8% on higher headcount and clinical trial investment, but were partially offset by spend discipline in training and R&D timing. Adjusted EBITDA turned positive at $1.9 million, a sharp improvement from last year’s loss, as operating leverage from higher sales outpaced cost escalation. Cash burn was seasonally high but expected to moderate, with a robust $161 million cash balance supporting ongoing initiatives.

• Open Ablation Volume Growth: Nearly 20% U.S. volume increase, with pricing uplift from Encompass Clamp adoption.
• Appendage Management Expansion: Durable growth across all markets, with LEAPS trial driving future addressable market.
• Pain Management Momentum: 39% global growth, with sternotomy opportunity and new probe innovation set for 2024.

Management’s guidance raise to 17-19% annual growth reflects confidence in underlying demand, but spending on clinical and commercial initiatives will drive variability in quarterly profitability for the remainder of 2023.

Executive Commentary

Strategic Positioning

1. Open Ablation: Encompass Clamp Drives Penetration

The Encompass Clamp, a surgical ablation tool, reached one-third of U.S. accounts within a year of launch, generating both volume and pricing tailwinds. Management sees room for further penetration, as the cardiac surgery market remains under-penetrated and demand for simplified, efficient ablation grows.

2. Clinical Trials: LEAPS Trial Accelerates Market Expansion

LEAPS, a 6,500-patient global trial, aims to validate prophylactic appendage management for stroke prevention in non-AFib cardiac surgery patients. Rapid enrollment is ahead of plan, with over 20 sites active and significant investment planned for 2023. Success could unlock a large, currently untapped market and establish new clinical standards.

3. Pain Management: Innovation and Market Expansion

The CryoSphere probe, used for post-operative pain management, posted 39% global growth, with new applications in thoracic and sternotomy procedures under evaluation. A next-generation probe is in development, with market expansion expected to accelerate in 2024 as sternotomy adoption ramps.

4. Hybrid Therapy: Building Foundation for Future Growth

Hybrid AF therapy, combining EpiSense technology with catheter ablation, continues to show superior outcomes in recent trials. While 2023 is framed as a building year, management expects deeper account penetration and workflow optimization to unlock robust growth in 2024 and beyond.

5. International Markets: Early-Stage Penetration

International sales rose 24%, with Europe leading on strong volume and new leadership driving disciplined market entry. Penetration remains low, suggesting a long runway for growth as awareness and access improve.

Key Considerations

AtriCure’s Q1 performance reflects a convergence of product innovation, clinical validation, and disciplined execution, but the durability of growth will depend on successful scaling of new products, continued clinical trial momentum, and competitive dynamics.

Key Considerations:

• Encompass Clamp Adoption Rate: Further U.S. penetration and international rollout are critical for sustaining open ablation growth.
• LEAPS Trial Execution: Accelerated enrollment and successful endpoints could redefine the addressable market for appendage management.
• Pain Management Expansion: New probe innovation and sternotomy application adoption are poised to drive above-corporate-average growth in 2024.
• Margin and Profitability Discipline: Cost control and operating leverage will be tested as R&D and clinical investments rise throughout the year.
• Competitive Threats: New entrants, particularly in pain management and ablation, could pressure pricing and share as markets mature.

Risks

Key risks include execution on large-scale clinical trials, especially LEAPS, which is pivotal for future appendage management expansion. Competitive threats are rising, particularly in pain management as new technologies target the same indications. Cost inflation and supply chain volatility could pressure margins, while investments in R&D and commercial teams may create near-term profit variability. Regulatory or reimbursement setbacks, especially for new products or expanded indications, could slow momentum.

Forward Outlook

For Q2 2023, AtriCure guided to:

• Modest sequential revenue increase, reflecting normal seasonality.
• Gross margin comparable to 2022, with variable cost and mix impacts.

For full-year 2023, management raised guidance:

• Revenue of $385 million to $392 million, up 17-19% year-over-year.
• Positive adjusted EBITDA of approximately $2 million, with variability expected in quarterly results.

Management highlighted several factors that will impact results:

• Ongoing investment in clinical trials and therapy awareness programs.
• Disciplined headcount and commercial expansion to drive adoption.

Takeaways

AtriCure’s Q1 2023 demonstrated accelerating adoption in core franchises and set the stage for multi-year growth, but the next phase will hinge on clinical trial execution, innovation pipeline, and spending discipline.

• Open Ablation Outperformance: Encompass Clamp’s rapid adoption is driving both volume and pricing leverage, with further penetration still ahead.
• Clinical and Innovation Pipeline: LEAPS and next-gen device launches are positioned to expand the addressable market and create new growth vectors.
• 2024 Growth Catalysts: Deeper hybrid therapy adoption, sternotomy market entry, and international expansion will be key watchpoints for investors.

Conclusion

AtriCure’s Q1 marked a step-change in open ablation adoption and clinical trial momentum, supporting a multi-year growth thesis. Execution on innovation, clinical validation, and margin discipline will determine the sustainability of recent gains as the company transitions from a building year to a period of broader market expansion.

Industry Read-Through

The strong adoption of AtriCure’s open ablation and appendage management devices signals robust demand for procedural innovation in cardiac surgery, with under-penetration remaining a major tailwind for device makers. Clinical trial investment and real-world evidence are increasingly central to expanding indications and reimbursement, a trend that will shape the strategies of both established and emerging cardiac device firms. Margin stability amid cost inflation and supply chain pressure highlights the importance of operational agility for all medtech players. As new competitors target pain management and ablation markets, the sector is likely to see both increased awareness and pricing pressure, reinforcing the need for differentiated outcomes and strong clinical data.

ATRC Healthcare Medical Devices Cardiac Surgery Ablation Clinical Trials Pain Management Innovation